MedTrace Logo

Omega-3 Fatty Acids in Autism Spectrum Disorders

NCT01695200 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-05-01

No results posted yet for this study

Summary

This is a 12-week open label trial to evaluate whether omega-3 fatty acids is effective in reducing the severity of autism and its comorbidities.

Conditions

  • Autism Spectrum Disorders

Interventions

DIETARY_SUPPLEMENT

Omega-3 fatty acids

Sponsors & Collaborators

  • National Healthcare Group, Singapore

    lead OTHER_GOV

Principal Investigators

  • Min Sung, MBBS, MMed · National Healthcare Group, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01695200 on ClinicalTrials.gov